 Home > Biochemistry News > Biotechnology News > NEJM: Pills extracted from human feces treat recurrent intestinal infections

NEJM: Pills extracted from human feces treat recurrent intestinal infections

 Last Update: 2022-02-20
 Source: Internet
 Author: User

Tags

chinese food dupont

new designing

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Studies have shown that it is used to fight diarrhea caused by repeated infections

Clostridium difficile,Microbiota transplant (fecal microbiota transplant, FMT, biological injection) provides an effective solution

One option, a pill containing bacterial spores isolated from human feces, has now been successful in a Phase 3 trial, paving the way for the first approval of this type of drug

"[For] most of the relapses we've seenClostridium difficile.

intestinal infection, the latter is common in older patients with other health problems and usually begins when antibiotics deplete their normal microbiota

In 2019, in a clinical trial unrelated to C.

The new pill, called SER-109, made by Seres Therapeutics, is extracted from human feces and purified to screen for resident microbes

Seres' purification process is designed to remove most pathogens known to pose safety risks to patients, said Vincent Young, a microbiologist and infectious disease physician at the University of Michigan in Ann Arbor, who was not involved in the new trial.

In 2016, Seres announced that its treatment failed to show a greater benefit than placebo in a phase 2 trial

The phase 3 trial, using a higher dose and more precise screening test, included 182 participants with C.

The findings, published in the New England Journal of Medicine, showed that 40 percent of the placebo group had a recurrence of C.

These results are similar to those of FMT, Kelly said

Other researchers wondered whether the new treatments could match the potency of the entire fecal microbiome

Young sees SER-109 as a "good bridge" from FMT to more tailored therapies, and he hopes that as researchers better analyze individual patients' microbiomes and figure out what kinds of microbes they need method will appear

Seres aims to submit an application for FDA approval of SER-109 by mid-2022

With the advent of FMT alternatives,

"I don't want to see the fecal bank model disappear completely," Kelly said

(Biology)

Original search:

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection

https://

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.